Standard Contracts
AMGEN INC. $1,250,000,000 1.650% SENIOR NOTES DUE 2028 $1,250,000,000 2.000% SENIOR NOTES DUE 2032 $1,150,000,000 2.800% SENIOR NOTES DUE 2041 $1,350,000,000 3.000% SENIOR NOTES DUE 2052 Underwriting AgreementUnderwriting Agreement • August 9th, 2021 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,250,000,000 principal amount of its 1.650% Senior Notes due 2028 (the “2028 Notes”), $1,250,000,000 principal amount of its 2.000% Senior Notes due 2032 (the “2032 Notes”), $1,150,000,000 principal amount of its 2.800% Senior Notes due 2041 (the “2041 Notes”) and $1,350,000,000 principal amount of its 3.000% Senior Notes due 2052 (the “2052 Notes,” and together with the 2028 Notes, the 2032 Notes and the 2041 Notes, the “Securities”) to be issued pursuant to the provisions of an Indenture dated as
